Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Gilead Sciences stock has delivered very strong gains over the past few years, yet current valuation checks still suggest the shares screen as inexpensive on several metrics. The question for investors is how that strong track record and the latest product approvals align with a profile that continues to lean cheap.

• Over 5 years the stock has returned about 143%, which puts recent moves in the context of a long, powerful run that investors now need to judge against today’s pricing.
• The recent approvals for Bixlenvo in HIV and the expanded European role for Trodelvy can support expectations for future cash flows. Any setbacks in clinical data, safety perceptions or uptake for these therapies may weigh on what investors are willing to pay.
• Gilead Sciences currently earns a high value score, and 5 out of 6 checks point to a stock that looks undervalued on the broader set of valuation measures.

The issue now is whether Gilead Sciences shares still offer enough valuation appeal after such a strong multi year performance.

Spot 44 high quality undervalued stocks that share Gilead Sciences' mix of strong multi year returns and a high value score, while they still screen as inexpensive on key fundamentals.

Is Gilead Sciences Still Cheap on Sales?

P/S is often a useful reference point for a company like Gilead Sciences where revenue and cash flow are key focus areas for investors. It provides a straightforward way to compare what the market pays for each dollar of sales against other biotechs.

Gilead Sciences currently trades on a P/S of 5.9x. This is below the biotech industry average of 13.2x and below the peer average of 7.3x. On Simply Wall St’s fair multiple framework, which looks at factors such as growth, margins, size and risk, a P/S of 10.0x would be more in line with Gilead Sciences. That fair ratio is comfortably above the current level, which indicates a discount on this metric.

Despite the recent approvals for Bixlenvo and the expanded role for Trodelvy in Europe, the stock still trades below what this model suggests would be a reasonable P/S multiple.

On the P/S multiple, Gilead Sciences stock appears undervalued compared with both its fair ratio and sector benchmarks.

See what the numbers say about this price — find out in our valuation breakdown.

The Gilead Sciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Gilead Sciences help you see what kind of future the current share price is effectively pointing to, including assumptions for growth, margins and earnings that could leave the stock worth much more or much less than it is today, and they sit on the company’s Community page. Where a single ratio or model suggests one number, these Narratives spell out the future that number relies on so you can monitor whether those conditions continue to hold.

Community views on Gilead Sciences are split between a pipeline driven upside case and a cautionary take that focuses on execution and pricing risk.

Bull case: 19% undervalued

"Gilead’s upcoming launches, including twice-yearly lenacapavir for PrEP, anito-cel cell therapy for multiple myeloma, and Trodelvy’s move into first-line triple-negative breast cancer, positively position the company to capture significantly larger addressable markets."

Read the full Bull Case to see why Gilead Sciences could be undervalued

Bear case: 13% overvalued

"Bear case: Execution risk (M&A integration, oncology competition, pricing pressure) and near-term EPS dilution."

Read the full Bear Case to see why Gilead Sciences could be overvalued

Do you think there's more to the story for Gilead Sciences? Head over to our Community to see what others are saying!

The Bottom Line

For Gilead Sciences, the valuation story still leans on a market multiple that screens as undervalued relative to peers and the tailored fair ratio. The high value score lines up with that signal and suggests the current price already bakes in a fair amount of caution on execution and pricing risk. From here, the key question is whether uptake and pricing for the newer therapies are strong enough to keep supporting that discount, or whether the current level already reflects the right balance between the pipeline opportunity and those risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com